Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Scher, H. I.
Beer, T. M.
Higano, C. S.
Taplin, M.
Efstathiou, E.
Anand, A.
Hung, D.
Hirmand, M.
Fleisher, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Washington, SCCA, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Medivation Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, Dana E.
    Shore, Neal
    Antonarakis, Emmanuel S.
    Berry, William R.
    Alumkal, Joshi J.
    Tutrone, Ronald
    Saleh, Mansoor N.
    Redfern, Charles H.
    Hauke, Ralph J.
    Liu, Glenn
    Steinbrecher, Jill Elise
    Danila, Daniel Costin
    Curley, Tracy
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [43] A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)
    Bilusic, M.
    Gulley, J. L.
    Heery, C.
    Apolo, A. B.
    Arlen, P. M.
    Rauckhorst, M.
    McMahon, S.
    Dahut, W. L.
    Schlom, J.
    Madan, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [44] DISEASE BURDEN OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN CHINA
    Ma, F. F.
    Liu, Q.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2020, 23 : S451 - S452
  • [45] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Hideyuki Akaza
    Hirotsugu Uemura
    Taiji Tsukamoto
    Seiichiro Ozono
    Osamu Ogawa
    Hideki Sakai
    Mototsugu Oya
    Mikio Namiki
    Satoshi Fukasawa
    Akito Yamaguchi
    Hiroji Uemura
    Yasuo Ohashi
    Hideki Maeda
    Atsushi Saito
    Kentaro Takeda
    Seiji Naito
    International Journal of Clinical Oncology, 2016, 21 : 773 - 782
  • [46] Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
    Lee, Daniel J.
    Cha, Eugene K.
    Dubin, Justin M.
    Beltran, Himisha
    Chromecki, Thomas F.
    Fajkovic, Harun
    Scherr, Douglas S.
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2012, 109 (07) : 968 - +
  • [47] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial
    Pan, C.
    Ghosh, P.
    Lara, P., Jr.
    Robles, D.
    Beckett, L.
    White, R. de Vere
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [49] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Ozono, Seiichiro
    Ogawa, Osamu
    Sakai, Hideki
    Oya, Mototsugu
    Namiki, Mikio
    Fukasawa, Satoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    Ohashi, Yasuo
    Maeda, Hideki
    Saito, Atsushi
    Takeda, Kentaro
    Naito, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
  • [50] A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
    Kuruma, Hidetoshi
    Matsumoto, Hiroaki
    Shiota, Masaki
    Bishop, Jennifer
    Lamoureux, Francois
    Thomas, Christian
    Briere, David
    Los, Gerrit
    Gleave, Martin
    Fanjul, Andrea
    Zoubeidi, Amina
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 567 - 576
12345